Loading...
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The last earnings update was 102 days ago. More info.
7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
---|---|---|---|---|---|---|
Momenta Pharmaceuticals (LZ1) | 9% | 12.8% | 2.3% | -12.4% | 33.6% | -11.5% |
DE Biotechs | 3.2% | -3.4% | -1% | -3.7% | 88.2% | 10.3% |
DE Market | 3% | 2.8% | -0.7% | -12.1% | 11.8% | 4.9% |
Below are the data sources, inputs and calculation used to determine the intrinsic value for Momenta Pharmaceuticals.
Data Point | Source | Value |
---|---|---|
Valuation Model | 2 Stage Free Cash Flow to Equity | |
Levered Free Cash Flow | Average of 7 Analyst Estimates (S&P Global) | See below |
Discount Rate (Cost of Equity) | See below | 11.2% |
Perpetual Growth Rate | 10-Year DE Government Bond Rate | 0.2% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
Data Point | Calculation/ Source | Result |
---|---|---|
Risk-Free Rate | 10-Year DE Govt Bond Rate | 0.2% |
Equity Risk Premium | S&P Global | 9.8% |
Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.13 |
Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.127 (1 + (1- 21%) (0%)) |
1.127 |
Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.13 |
Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.127 * 9.77%) |
11.24% |
Discounted Cash Flow Calculation for DB:LZ1 using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Momenta Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
2019 | 2020 | 2021 | 2022 | 2023 | |
Levered FCF (USD, Millions) | -120.75 | -142.80 | -145.00 | -2.97 | 243.50 |
Source | Analyst x4 | Analyst x3 | Analyst x2 | Analyst x3 | Analyst x2 |
Present Value Discounted (@ 11.24%) |
-108.54 | -115.39 | -105.32 | -1.94 | 142.92 |
Present value of next 5 years cash flows | $-188.27 |
Calculation | Result | |
---|---|---|
Terminal Value |
= FCF2023
× (1 + g) ÷ (Discount Rate – g)
= $243.50 × (1 + 0.23%) ÷ (11.24% – 0.23%) |
$2,215.29 |
Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)5
= $2,215.29 ÷ (1 + 11.24%)5 |
$1,300.26 |
Calculation | Result | |
---|---|---|
Total Equity Value |
= Present value of next 5 years cash flows +
Terminal Value
= $-188.27 + $1,300.26 |
$1,111.99 |
Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $1,111.99 / 98.24 |
$9.39 |
Calculation | Result | |
---|---|---|
Non-primary Listing Adjustment Factor |
1 share in DB:LZ1
represents 0.82968x
of
NasdaqGS:MNTA
(This could be a different class, a depositary receipt, a different currency, or all of these things.) |
0.82968x |
Value per Share (Listing Adjusted, EUR) |
= Value per Share (USD) x Listing Adjustment Factor
= $ 11.32 x 0.82968 |
€9.39 |
Value per share (EUR) | From above. | €9.39 |
Current discount | Discount to share price of
€11.35
= -1 x (€11.35 - €9.39) / €9.39 |
-20.9% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Data Point | Source | Value |
---|---|---|
Earnings Per Share * | Company Filings (2018-09-30) in USD | $-2.03 |
NasdaqGS:MNTA Share Price ** | NasdaqGS (2019-02-15) in USD | $13.68 |
Europe Biotechs Industry PE Ratio | Median Figure of 26 Publicly-Listed Biotechs Companies | 24.27x |
Germany Market PE Ratio | Median Figure of 419 Publicly-Listed Companies | 18.21x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Momenta Pharmaceuticals.
Calculation | Outcome | |
---|---|---|
PE Ratio | = NasdaqGS:MNTA Share Price ÷ EPS (both in USD) = 13.68 ÷ -2.03 |
-6.75x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value |
---|---|---|
PE Ratio | See PE Ratio Section | -6.75x |
Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts |
24.1%per year |
Europe Biotechs Industry PEG Ratio | Median Figure of 21 Publicly-Listed Biotechs Companies | 1.45x |
Germany Market PEG Ratio | Median Figure of 276 Publicly-Listed Companies | 1.42x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value |
---|---|---|
Book Value per Share | Company Filings (2018-09-30) in USD | $3.22 |
NasdaqGS:MNTA Share Price * | NasdaqGS (2019-02-15) in USD | $13.68 |
Germany Biotechs Industry PB Ratio | Median Figure of 14 Publicly-Listed Biotechs Companies | 2.39x |
Germany Market PB Ratio | Median Figure of 566 Publicly-Listed Companies | 1.79x |
Calculation | Outcome | |
---|---|---|
PB Ratio | = NasdaqGS:MNTA Share Price ÷ Book Value per Share (both in USD) = 13.68 ÷ 3.22 |
4.25x |
* Primary Listing of Momenta Pharmaceuticals.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value (per year) |
---|---|---|
DB:LZ1 Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts | 24.1% |
DB:LZ1 Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts | 12.3% |
Germany Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 29.7% |
Germany Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 25.6% |
Germany Market Earnings Growth Rate | Market Cap Weighted Average | 9.6% |
Germany Market Revenue Growth Rate | Market Cap Weighted Average | 4.7% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Data Point | Source | Value |
---|---|---|
Past Financials | Company Filings (4 months ago) | See Below |
Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
---|---|---|---|---|
2023-12-31 | 132 | -58 | -64 | 3 |
2022-12-31 | 84 | -56 | -62 | 4 |
2021-12-31 | 84 | -51 | -42 | 4 |
2020-12-31 | 78 | -108 | -77 | 6 |
2019-12-31 | 73 | -96 | -72 | 7 |
2018-12-31 | 50 | -176 | -213 | 5 |
Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
---|---|---|---|
2018-09-30 | 97 | -161 | -154 |
2018-06-30 | 107 | -144 | -137 |
2018-03-31 | 117 | -132 | -104 |
2017-12-31 | 139 | -30 | -88 |
2017-09-30 | 108 | 53 | -60 |
2017-06-30 | 114 | 55 | -45 |
2017-03-31 | 116 | 57 | -29 |
2016-12-31 | 110 | 8 | -21 |
2016-09-30 | 98 | -60 | -92 |
2016-06-30 | 82 | -36 | -104 |
2016-03-31 | 101 | -29 | -85 |
2015-12-31 | 90 | -72 | -83 |
*GAAP earnings excluding extraordinary items.
Data Point | Source | Value |
---|---|---|
Past Financials | Company Filings (4 months ago) | See Below |
Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
All data from Momenta Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
---|---|---|---|---|
2023-12-31 | -1.38 | -1.38 | -1.38 | 1.00 |
2022-12-31 | -1.07 | -1.07 | -1.07 | 1.00 |
2021-12-31 | -0.79 | -0.79 | -0.79 | 1.00 |
2020-12-31 | -0.73 | -0.73 | -0.73 | 1.00 |
2019-12-31 | -0.84 | -0.76 | -0.91 | 2.00 |
2018-12-31 | -2.71 | -2.70 | -2.71 | 2.00 |
Date (Data in USD Millions) | EPS * |
---|---|
2018-09-30 | -2.03 |
2018-06-30 | -1.82 |
2018-03-31 | -1.39 |
2017-12-31 | -1.20 |
2017-09-30 | -0.84 |
2017-06-30 | -0.64 |
2017-03-31 | -0.42 |
2016-12-31 | -0.31 |
2016-09-30 | -1.34 |
2016-06-30 | -1.53 |
2016-03-31 | -1.28 |
2015-12-31 | -1.32 |
*GAAP earnings excluding extraordinary items.
How has Momenta Pharmaceuticals performed over the past 5 years?
All data from Momenta Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
---|---|---|---|---|
2018-09-30 | 97.38 | -154.06 | 79.41 | 80.09 |
2018-06-30 | 106.58 | -136.95 | 79.67 | 82.01 |
2018-03-31 | 117.12 | -103.97 | 79.71 | 79.40 |
2017-12-31 | 138.88 | -88.10 | 82.21 | 76.76 |
2017-09-30 | 108.47 | -60.32 | 84.55 | 79.64 |
2017-06-30 | 113.52 | -44.67 | 79.60 | 78.89 |
2017-03-31 | 116.38 | -28.75 | 71.92 | 80.42 |
2016-12-31 | 109.62 | -21.00 | 64.47 | 78.71 |
2016-09-30 | 97.82 | -91.71 | 60.67 | 78.23 |
2016-06-30 | 82.47 | -104.21 | 57.38 | 77.62 |
2016-03-31 | 100.94 | -85.45 | 55.81 | 77.67 |
2015-12-31 | 89.65 | -83.31 | 48.05 | 73.45 |
2015-09-30 | 88.44 | -70.13 | 44.80 | 71.59 |
2015-06-30 | 83.98 | -69.18 | 43.45 | 71.29 |
2015-03-31 | 50.03 | -93.12 | 41.34 | 69.24 |
2014-12-31 | 52.25 | -98.60 | 45.16 | 74.03 |
2014-09-30 | 43.82 | -112.68 | 44.89 | 75.39 |
2014-06-30 | 45.24 | -108.96 | 42.76 | 74.29 |
2014-03-31 | 38.65 | -111.65 | 43.06 | 72.25 |
2013-12-31 | 35.47 | -108.41 | 41.06 | 69.75 |
2013-09-30 | 35.44 | -96.02 | 39.58 | 66.01 |
2013-06-30 | 29.79 | -96.46 | 41.61 | 96.27 |
2013-03-31 | 47.30 | -77.78 | 42.44 | 79.40 |
2012-12-31 | 63.92 | -58.65 | 43.68 | 62.66 |
2012-09-30 | 80.65 | -42.22 | 44.02 | 47.39 |
2012-06-30 | 163.49 | 43.94 | 44.51 | |
2012-03-31 | 229.12 | 118.37 | 41.36 |
*GAAP earnings excluding extraordinary items.
How is Momenta Pharmaceuticals's financial health and their level of debt?
All data from Momenta Pharmaceuticals Company Filings, last reported 4 months ago.
Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
---|---|---|---|
2018-09-30 | 248.76 | 0.00 | 275.08 |
2018-06-30 | 281.69 | 0.00 | 310.83 |
2018-03-31 | 334.42 | 0.00 | 323.90 |
2017-12-31 | 374.15 | 0.00 | 342.67 |
2017-09-30 | 360.51 | 0.00 | 418.79 |
2017-06-30 | 386.86 | 0.00 | 446.55 |
2017-03-31 | 370.32 | 0.00 | 433.75 |
2016-12-31 | 371.91 | 0.00 | 353.15 |
2016-09-30 | 325.78 | 0.00 | 308.96 |
2016-06-30 | 334.64 | 0.00 | 336.92 |
2016-03-31 | 351.48 | 0.00 | 345.79 |
2015-12-31 | 369.98 | 0.00 | 350.04 |
2015-09-30 | 393.26 | 0.00 | 374.87 |
2015-06-30 | 416.64 | 0.00 | 377.17 |
2015-03-31 | 216.70 | 0.00 | 198.70 |
2014-12-31 | 206.37 | 0.00 | 191.53 |
2014-09-30 | 200.36 | 0.00 | 176.46 |
2014-06-30 | 225.37 | 0.00 | 202.28 |
2014-03-31 | 247.75 | 0.00 | 223.95 |
2013-12-31 | 269.84 | 0.00 | 245.68 |
2013-09-30 | 295.99 | 0.00 | 275.90 |
2013-06-30 | 314.92 | 0.00 | 300.16 |
2013-03-31 | 340.05 | 0.00 | 324.20 |
2012-12-31 | 360.49 | 0.00 | 340.60 |
2012-09-30 | 374.72 | 0.00 | 361.82 |
2012-06-30 | 396.31 | 0.00 | 372.31 |
2012-03-31 | 402.19 | 0.00 | 382.26 |
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
What is Momenta Pharmaceuticals's current dividend yield, its reliability and sustainability?
Data Point | Source | Value |
---|---|---|
Past Annualized Dividend Yield | S&P Global Market Data | See Below |
Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
Future Dividends per Share Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
Europe Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 10 Stocks | 0.9% |
Germany Market Average Dividend Yield | Market Cap Weighted Average of 332 Stocks | 3.1% |
Germany Minimum Threshold Dividend Yield | 10th Percentile | 0.9% |
Germany Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
Germany Top 25% Dividend Yield | 75th Percentile | 4% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
---|---|---|
2023-12-31 | ||
2022-12-31 | ||
2021-12-31 | ||
2020-12-31 | 0.00 | 1.00 |
2019-12-31 | 0.00 | 1.00 |
2018-12-31 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Mr. Craig A. Wheeler has been the Chief Executive Officer and President of Momenta Pharmaceuticals Inc. since September 12, 2006 and August 22, 2006, respectively. Mr. Wheeler has been an Executive Director at Momenta Pharmaceuticals Inc. since August 22, 2006. He was Principal Financial Officer and Principal Accounting Officer of Momenta Pharmaceuticals since May 8, 2018 to October 5, 2018. He led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX and once-daily COPAXONE. He has also overseen the growth into a diversified business, with a development pipeline of biosimilar biologics as well as novel therapeutics for oncology and autoimmune indications at Momenta Pharmaceuticals. He served as the Board Chairman, Treasurer and Secretary of Generic Pharmaceutical Association until February 22, 2016. Mr. Wheeler served as a Vice President of Chiron Corp. from August 2001 to June 2006. Prior to joining Momenta, he served as the President of Chiron Biopharmaceuticals, a division of Chiron Corp. from August 2001 to June 2006. He was responsible for all aspects of the Biopharmaceuticals business unit, including commercial, research, development and manufacturing. During his tenure at Chiron, he led the restructuring of the business unit to refocus on oncology and infectious disease. Mr. Wheeler served as a Partner and served as a Senior Member of health care practice at The Boston Consulting Group and a key contributor to its practice in hospital strategy, disease management and pharmaceutical capabilities from August 1988 to August 2001. He began his career at Merck & Company, Inc.'s MSDRL research unit. Mr. Wheeler served as a Senior Engineer in process development at Merck's MSDRL research unit. He served as the Leader of Scientist's Network at The Boston Consulting Group. In partnership with Rockefeller Foundation, he has joined Global Alliance for TB Drug Development. He served as a Financial Analyst for Hybritech. He has extensive professional experience in the biotechnology and healthcare industries. Mr. Wheeler served as the Chairman of Avanir Pharmaceuticals, Inc. from May 3, 2007 to January 13, 2015 and GPhA from 2014 to February 2016. He serves as a Director of Association for Accessible Medicines. He has been a Director of Amicus Therapeutics, Inc. since June 10, 2016. Mr. Wheeler has extensive pharmaceutical industry knowledge and leadership experience, including his demonstrated expertise in drug development, manufacturing and the technical issues facing growing biopharmaceutical companies. Mr. Wheeler serves as a Director of California Healthcare Institute. He serves as a Member of the Chief Executive Officer Roundtable on Cancer, Inc. He also serves on the IBM Life Science Strategic Advisory Council and the Whitehead Institute for Biomedical Research's Board of Associates. He served as a Director of Association for Accessible Medicines (a/k/a Generic Pharmaceutical Association) until February 22, 2016. Mr. Wheeler served as a Director of Avanir Pharmaceuticals, Inc. from September 27, 2005 to January 13, 2015. In 2011, Mr. Wheeler was an E&Y Entrepreneur of the Year Regional Award winner. Mr. Wheeler holds BS and an MS Degree in Chemical Engineering from Cornell University and an MBA from the Wharton School of the University of Pennsylvania, where he majored in Marketing and Finance.
Average tenure and age of the Momenta Pharmaceuticals management team in years:
Average tenure and age of the Momenta Pharmaceuticals board of directors in years:
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company’s complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company’s novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Name: | Momenta Pharmaceuticals, Inc. |
LZ1 | |
Exchange: | DB |
Founded: | 2001 |
$1,192,075,604 | |
98,241,296 | |
Website: | http://www.momentapharma.com |
Address: |
Momenta Pharmaceuticals, Inc. 675 West Kendall Street, Cambridge, Massachusetts, 02142, United States |
Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
---|---|---|---|---|---|---|---|
NasdaqGS | MNTA | Common Stock | Nasdaq Global Select | US | USD | 22. Jun 2004 | |
DB | LZ1 | Common Stock | Deutsche Boerse AG | DE | EUR | 22. Jun 2004 |
Biotechnology | |
Pharmaceuticals & Biotech |
Area | Date (UTC time) |
---|---|
Company Analysis updated: | 2019/02/17 20:33 |
End of day share price update: | 2019/02/15 00:00 |
Last estimates confirmation: | 2019/01/06 |
Last earnings filing: | 2018/11/07 |
Last earnings reported: | 2018/09/30 |
Last annual earnings reported: | 2017/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.